TMCnet News
Circulating Tumor Cell Diagnostics Market - Drivers and Forecasts by TechnavioTechnavio analysts forecast the global circulating tumor cell (CTC) diagnostics market to grow at a CAGR of over 9% during the forecast period, according to their latest report. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171019005910/en/ 
Technavio has published a new report on the global circulating tumor cell (CTC (News - Alert)) diagnostics market from 2017-2021. (Graphic: Business Wire) The research study covers the present scenario and growth prospects of the global CTC diagnostics market for 2017-2021. CTC diagnostics helps in the identification of deoxyribonucleic acid (DNA) shed by tumor cells. CTCs are cancerous cells which detach from primary tumor and migrate to the bloodstream or lymphatic system of the patient. The market is growing steadily in developed countries and has a high growth potential in emerging countries such as India, China, and Brazil. The outsourcing of biopharmaceutical companies to the CROs is increasing, impacting the adoption rate in the emerging economies. Acquisition of CELLSEARCH Circulating Tumor Cell System from Janssen Diagnostics by Menarini Silicon Biosystems was one of the pivotal moments in the global CTC diagnostics market. This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free. Technavio analysts highlight the following three factors that are contributing to the growth of the global CTC diagnostics market:
Looking for more information on this market? Request a free sample report Technavio's sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more. Increasing incidences of cancer Cancer is one of the lethal diseases, which has increased mortality rate worldwide. Various types of cancer occur due to genetic changes, high consumption of alcohol, smoking, and other lifestyle changes. The overall burden of cancer is increasing across the globe. Some of the most common type of cancers are breast cancer, colon cancer, prostate cancer, lung and bronchus cancer, kidney cancer, pancreatic cancer, leukemia, and melanoma of skin. According to the OECD, the death rate is high in colon cancer cases. Germany and Italy have contributed highest to the mortality rate of cancer in the region. The scenario remains same in APAC, where the diagnosis of cancer suffers due to negligence, lack of awareness, and late diagnosis of cancer. However, the global CTC diagnostics market is propelled by the rising incidence of cancer worldwide. Demand for CTC diagnostics for personalized cancer treatment Srinivas Sashidhar, a lead in-vitro diagnostics research analyst at Technavio, says, "CTC-based diagnostic tests are trending in the market for the diagnosis of cancer. CTC-based diagnostic test is a regular blood test used for tumor analysis. It is being preferred over painful bone marrow examination and surgical biopsies for the diagnosis of cancer metastasis. CTC analysis and quantification based on molecular research helps in the development of personalized cancer treatment." The demand for CTC-based diagnostics is increasing because it offers faster diagnosis, and the analyzers have user-friendly interface. Polymerase chain reaction (PCR (News - Alert))-based identification methods are one of the most effective and sensitive methods for CTC genetic profiling. PCR-based methods are preferred over molecular identification and other protein-based methods for the detection of CTCs. Rising demand for liquid biopsy With the rising incidence of cancer, there is also a growing demand for improved detection and diagnosis in the market. Blood test for the screening of sticky DNA molecules released by the dead cancer cells helps in cancer diagnosis at an early stage. Liquid biopsy has been in demand for the early detection of cancer. It is one of the new technologies introduced in the medical field. The collection of tumor tissue through biopsies is the gold standard for diagnosis and treatment of cancer. This diagnosis eliminates the use of biomarkers for the early detection of cancer. There are various academic research institutes, cancer associations and market vendors engaged in the development of liquid biopsy technology. Top vendors:
Browse Related Reports:
About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. If you are interested in more information, please contact our media team at [email protected].
View source version on businesswire.com: http://www.businesswire.com/news/home/20171019005910/en/ |
